Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/76135
Authors: 
Sennhauser, Michèle
Zweifel, Peter
Year of Publication: 
2009
Series/Report no.: 
Working Paper, Socioeconomic Institute, University of Zurich 0914
Abstract: 
This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals interviewed in 2007, 200 suffered from type 1 diabetes, 150 from insulin-treated type 2 diabetes, and 150 from insulin-naive type 2 diabetes. The long-acting insulin analogue 'Insulin Detemir' is compared to human insulin as the status quo. The DCE contains two price attributes, copayment and increased contributions to health insurance. As one would expect, non-affected non-diabetics and insulin-naive diabetics exhibit higher willingness-to-pay (WTP) values through copayment (adjusted for probability of contracting diabetes), while affected type 1 and insulin-treated type 2 diabetics have higher WTP through increased contributions. However, WTP values exceed the extra treatment cost in both financing alternatives, justifying inclusion of the innovation in the benefit list from a cost-benefit point of view.
Subjects: 
health insurance
discrete-choice experiment
preferences
diabetes
JEL: 
I11
H51
I18
Document Type: 
Working Paper

Files in This Item:
File
Size
272.63 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.